SCHEMBL16201348

SCHEMBL16201348

CCCN(C)Cc1c[nH]nc1-c1ccc(F)cc1Cl

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CDC7 O00311 1/20 0.34
DBF4 Q9UBU7 1/20 0.34
CRHR1 P34998 4/20 0.33
HTR2A P28223 4/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
MEN1 O00255 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TP53 P04637 1/20 0.32
HSD11B1 P28845 1/20 0.32
HTR1A P08908 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201367 0.91 ALDH1A1 (0.35) SLC6A2SLC6A4SLC6A3ALDH1A1KDM4E
SCHEMBL16201179 0.89 CARM1 (0.41) NISCHSLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL16201352 0.88 CRHR1 (0.43) CRHR1TDP1
SCHEMBL16201356 0.88 ALDH1A1 (0.41) ALDH1A1KDM4EHTR2AMEN1GAA
SCHEMBL16201413 0.87 NMT1 (0.40) ALDH1A1KDM4ECRHR1HTR2AMEN1
SCHEMBL16201377 0.87 CRHR1 (0.38) SLC6A4ALDH1A1KDM4ECRHR1HTR2A
SCHEMBL16201389 0.85 PRMT6 (0.38) SLC6A2SLC6A4CRHR1HTR2APTGDR2
SCHEMBL16201394 0.85 CRHR1 (0.40) SLC6A4ALDH1A1KDM4ECDC7DBF4
SCHEMBL16201401 0.85 ALDH1A1 (0.44) ALDH1A1KDM4ECRHR1HTR2AMEN1
SCHEMBL16201411 0.84 ALDH1A1 (0.39) NISCHSLC6A2SLC6A4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 NISCH 3918/4885SLC6A2 1784/4885SLC6A4 2514/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 NISCH 3839/4885SLC6A2 2703/4885SLC6A4 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.